FDA

Brain inflammation
#Bristol Myers Squibb #FDA #Neuroscience #PureTech #Schizophrenia

New approach to schizophrenia treatment secures US approval

The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care. “Schizophrenia… Read More

#News #Regulatory #Trending News

FDA headquarters
#FDA #Monoclonal antibodies #Myeloma #Oncology #Sanofi

FDA approves Sarclisa combination for multiple myeloma

The US Food and Drug Administration (FDA) has approved Sanofi’s anti-CD38 monoclonal antibody isatuximab-irfc (Sarclisa) for newly diagnosed multiple myeloma. It is approved in combination with bortezomib, lenalidomide, and dexamethasone for adults with who are not eligible for autologous stem cell transplant (ASCT). The efficacy of the treatment was evaluated… Read More

#News #Regulatory

FDA
#FDA #IntraBio #Rare disease #Zevra Therapeutics

FDA approves two treatments for Niemann-Pick Disease

This week, the US Food and Drug Administration (FDA) has approved both Zevra Therapeutics’ Miplyffa (arimoclomol) and IntraBio’s Aqneursa (levacetylleucine) for Neimann-Pick disease, type C (NPC). Miplyffa, in combination with the enzyme inhibitor miglustat, is approved to treat neurological symptoms associated with NPC in adults and children two years of… Read More

#News #Regulatory

Myeloma
#CAR-T #Cell and gene therapy #Cell therapy #FDA #Myeloma #Poseida Therapeutics #Roche

‘Off-the-shelf’ CAR-T secures FDA advanced therapy designation

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Roche and Poseida Therapeutics’ P-BCMA-ALLO1. P-BCMA-ALLO1 is an investigational stem cell memory T cell (TSCM)-based allogeneic CAR-T cell therapy in Phase I/Ib clinical development for the treatment of patients with relapsed/refractory multiple myeloma. The… Read More

#News #Regulatory

#Autoimmune disease #CAR-T #Cell therapy #FDA #Lupus #Synthekine

CAR-T and orthogonal IL-2 therapy for lupus fast-tracked by FDA

The US Food and Drug Administration (FDA) has granted fast track designation to SYNCAR-001 + STK-009. The treatment is indicated for patients with severe, refractory systemic lupus erythematosus (SLE), without the use of lymphodepletion. The fast-track designation follows investigational new drug (IND) clearance for a Phase I study evaluating SYNCAR-001… Read More

#News #Regulatory

Liver cancer
#Cell therapy #FDA #Grit Biotechnology #Oncology #Solid tumours

FDA clears genetically engineered TIL therapy for solid tumour trials

Grit Biotechnology has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) for its genetically engineered tumour-infiltrating lymphocyte (TIL) product GT201. The therapy is now approved by both the FDA and China Center for Drug Evaluation (CDE) to enter clinical trials in both countries for… Read More

#Cancer Research #News #Regulatory

#European Commission #FDA #Regulatory #Scottish Medicines Consortium (SMC)

New DDW Highlights podcast: 27 August 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It’s been a busy week for medical regulatory agencies, with a number of key… Read More

#News

#European Commission #FDA #Regulatory #Scottish Medicines Consortium (SMC)

New DDW Highlights vodcast: 27 August 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   It’s been a busy week… Read More

#News

#European Commission #FDA #Regulatory #Scottish Medicines Consortium (SMC)

This week in drug discovery (19-23 August) 

News round-up for 19-23 August by DDW Senior Digital Content Editor Diana Spencer. It’s been a busy week for medical regulatory agencies, with a number of key decisions made on therapies for graft-versus-host-disease, neuroendocrine carcinoma, haemophilia B, lymphoma and non-small cell lung cancer. The top stories:… Read More

#News

Non-small cell lung cancer
#FDA #Johnson & Johnson #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology

FDA approves combination therapy for non-small lung cancer

The US Food and Drug Administration (FDA) has approved lazertinib (Lazcluze) in combination with amivantamab-vmjw (Rybrevant) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). It is approved in NSCLC with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations,… Read More

#News #Regulatory

FDA headquarters
#Bispecific Antibodies #FDA #Oncology #Orphan drugs #Phanes Therapeutics

Neuroendocrine carcinoma drug granted orphan status

Phanes Therapeutics' PT217 has received orphan drug designation (ODD) for neuroendocrine carcinoma (NEC) from the US Food and Drug Administration (FDA). PT217 is a first-in-class bispecific antibody targeting delta-like ligand 3 (DLL3) and cluster of differentiation 47 (CD47) being developed for patients with NEC. NEC is known to be the… Read More

#Cancer Research #News #Regulatory

Stem cells
#FDA #Graft vs Host Disease #Incyte #Syndax Pharmaceuticals

FDA approves Niktimvo for chronic graft-versus-host disease

The US Food and Drug Administration (FDA) has approved axatilimab-csfr (Niktimvo), a colony stimulating factor-1 receptor-blocking antibody, for the treatment of chronic graft-versus-host disease (cGVHD). It is approved for use after the failure of at least two prior lines of systemic therapy in adult and paediatric patients weighing at least… Read More

#News #Regulatory

#Cancer drug targets #Cancer research #Cancer therapeutics #FDA #Oncology

New DDW Highlights podcast: 19 August 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The chosen news highlights this week all feature advances in drug development in oncology… Read More

#News

#Cancer drug targets #Cancer research #Cancer therapeutics #FDA #Oncology

New DDW Highlights vodcast: 19 August 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   The chosen news highlights this… Read More

#News

#Cancer drug targets #Cancer research #Cancer therapeutics #FDA #Oncology

This week in drug discovery (12-16 August) 

News round-up for 12-16 August by DDW Senior Digital Content Editor Diana Spencer. The chosen news highlights this week all feature advances in drug development in oncology indications and reflect the breadth of therapeutic approaches to cancer treatment. The top stories: Genetic causes of… Read More

#News

T cell attacking cancer cell
#Cell therapy #Citius Pharmaceuticals #FDA #Lymphoma #Mergers and acquisitions #Oncology

Citius Oncology launches following FDA approval of Lymphir

The US Food and Drug Administration (FDA) has approved Lymphir (denileukin diftitox-cxdl) for the second-line treatment of r/r cutaneous T-cell lymphoma (CTCL), making it Citius Pharma’s first product approved in the US. Lymphir is a novel immunotherapy and the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on… Read More

#Business & Investment #News #Regulatory